[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

CY1123044T1 - Νεες ενωσεις - Google Patents

Νεες ενωσεις

Info

Publication number
CY1123044T1
CY1123044T1 CY20201100326T CY201100326T CY1123044T1 CY 1123044 T1 CY1123044 T1 CY 1123044T1 CY 20201100326 T CY20201100326 T CY 20201100326T CY 201100326 T CY201100326 T CY 201100326T CY 1123044 T1 CY1123044 T1 CY 1123044T1
Authority
CY
Cyprus
Prior art keywords
derivatives
unions
new
new unions
diseases
Prior art date
Application number
CY20201100326T
Other languages
English (en)
Inventor
Gerard M P GIBLIN
David T Macpherson
David R Witty
Steven J STANWAY
Original Assignee
Convergence Pharmaceuticals Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Convergence Pharmaceuticals Limited filed Critical Convergence Pharmaceuticals Limited
Publication of CY1123044T1 publication Critical patent/CY1123044T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Η εφεύρεση αφορά σε σπείρο παράγωγα, στη χρήση των εν λόγω παραγώγων στη θεραπεία ασθενειών και καταστάσεων που προκαλούνται με ρύθμιση των περιορισμένης ηλεκτρικής τάσης διαύλων νατρίου, σε συνθέσεις που περιέχουν τα εν λόγω παράγωγα και μεθόδους για παρασκευή αυτών.
CY20201100326T 2012-05-22 2020-04-07 Νεες ενωσεις CY1123044T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261650325P 2012-05-22 2012-05-22
GB201209015A GB201209015D0 (en) 2012-05-22 2012-05-22 Novel compounds
US201361773710P 2013-03-06 2013-03-06
EP13725439.7A EP2861594B1 (en) 2012-05-22 2013-05-22 Novel compounds
PCT/GB2013/051336 WO2013175206A1 (en) 2012-05-22 2013-05-22 Novel compounds

Publications (1)

Publication Number Publication Date
CY1123044T1 true CY1123044T1 (el) 2021-10-29

Family

ID=46546493

Family Applications (2)

Application Number Title Priority Date Filing Date
CY20161101143T CY1118274T1 (el) 2012-05-22 2016-11-09 7-μεθυλ-2-[4-μεθυλ-6-[4-(τριφθορομεθυλ)-φαινυλ]πυριμιδιν-2-υλ]-1,7-διαζασπειρο[4.4]εννεαν-6-ονη
CY20201100326T CY1123044T1 (el) 2012-05-22 2020-04-07 Νεες ενωσεις

Family Applications Before (1)

Application Number Title Priority Date Filing Date
CY20161101143T CY1118274T1 (el) 2012-05-22 2016-11-09 7-μεθυλ-2-[4-μεθυλ-6-[4-(τριφθορομεθυλ)-φαινυλ]πυριμιδιν-2-υλ]-1,7-διαζασπειρο[4.4]εννεαν-6-ονη

Country Status (28)

Country Link
US (7) US9376445B2 (el)
EP (3) EP2861602B1 (el)
JP (3) JP2015517562A (el)
KR (2) KR20200113027A (el)
CN (2) CN107344942B (el)
AU (3) AU2013265001B2 (el)
BR (1) BR112014029280B1 (el)
CA (1) CA2873956C (el)
CY (2) CY1118274T1 (el)
DK (2) DK2861602T3 (el)
EA (1) EA025579B1 (el)
ES (3) ES2602193T3 (el)
GB (1) GB201209015D0 (el)
HK (1) HK1209423A1 (el)
HR (2) HRP20161349T1 (el)
HU (2) HUE031664T2 (el)
IL (4) IL235805A (el)
IN (1) IN2014MN02393A (el)
LT (2) LT3106464T (el)
MX (1) MX355303B (el)
PL (2) PL2861602T3 (el)
PT (2) PT3106464T (el)
RS (2) RS55415B1 (el)
SG (2) SG10201703527WA (el)
SI (2) SI3106464T1 (el)
SM (2) SMT202000210T1 (el)
WO (2) WO2013175205A1 (el)
ZA (1) ZA201408253B (el)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
EP3687533A4 (en) * 2017-09-28 2021-01-20 Biogen Inc. NEW SALT
WO2019075073A2 (en) 2017-10-10 2019-04-18 Biogen Inc. PROCESS FOR THE PREPARATION OF SPIRO DERIVATIVES
WO2022133097A1 (en) * 2020-12-17 2022-06-23 Biogen Ma Inc. Synthesis of compounds that modulate use-dependent voltage-gated sodium channels

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2355157T3 (es) * 2002-07-05 2011-03-23 Targacept, Inc. Compuestos diazaspirocíclico n-arilo y métodos de preparación y uso de las mismas.
TW200728258A (en) 2005-10-10 2007-08-01 Glaxo Group Ltd Novel compounds
TW200730494A (en) 2005-10-10 2007-08-16 Glaxo Group Ltd Novel compounds
US8143306B2 (en) 2005-10-10 2012-03-27 Convergence Pharmaceuticals Limited Methods of treating bipolar disorders
ATE472529T1 (de) 2005-10-10 2010-07-15 Glaxo Group Ltd Prolinamidderivate als natriumkanalmodulatoren
GB0520578D0 (en) * 2005-10-10 2005-11-16 Glaxo Group Ltd Novel compounds
JP2009511599A (ja) * 2005-10-12 2009-03-19 バーテックス ファーマシューティカルズ インコーポレイテッド 電位依存性イオンチャネルの調整剤としてのビフェニル誘導体
WO2007084314A2 (en) * 2006-01-12 2007-07-26 Incyte Corporation MODULATORS OF 11-ß HYDROXYL STEROID DEHYDROGENASE TYPE 1, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USING THE SAME
AU2007307638A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Spiro (furo [3, 2-C] pyridine-3-3 ' -indol) -2' (1'H)-one derivatives and related compounds for the treatment of sodium-channel mediated diseases, such as pain
AU2007307635A1 (en) 2006-10-12 2008-04-17 Xenon Pharmaceuticals Inc. Tricyclic spiro-oxindole derivatives and their uses as therapeutic agents
JP2010516731A (ja) * 2007-01-24 2010-05-20 グラクソ グループ リミテッド ２−メトキシ−５−（５−トリフルオロメチル−テトラゾール−１−イル）−ベンジル］−（２ｓ−フェニル−ピペリジン−３ｓ−イル）−アミンを含む医薬組成物
GB0701366D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0701365D0 (en) 2007-01-24 2007-03-07 Glaxo Group Ltd Novel pharmaceutical compositions
GB0706630D0 (en) * 2007-04-04 2007-05-16 Glaxo Group Ltd Novel compounds
AR077252A1 (es) * 2009-06-29 2011-08-10 Xenon Pharmaceuticals Inc Enantiomeros de compuestos de espirooxindol y sus usos como agentes terapeuticos
PT2477964E (pt) 2009-09-14 2015-06-04 Convergence Pharmaceuticals Processo para a preparação de derivados de alfa-carboxamida
GB201122113D0 (en) 2011-12-22 2012-02-01 Convergence Pharmaceuticals Novel compounds
KR20140139000A (ko) * 2012-03-21 2014-12-04 인터디지탈 패튼 홀딩스, 인크 무선 네트워크에서 다른 이동국에 의한 이동국 세션의 스폰서링
GB201209015D0 (en) 2012-05-22 2012-07-04 Convergence Pharmaceuticals Novel compounds
GB201209670D0 (en) 2012-05-31 2012-07-18 Convergence Pharmaceuticals Novel compounds

Also Published As

Publication number Publication date
US10010551B2 (en) 2018-07-03
AU2018201653B2 (en) 2019-05-02
JP6169687B2 (ja) 2017-07-26
RS55415B1 (sr) 2017-04-28
PL3106464T3 (pl) 2020-11-16
IL280595A (en) 2021-03-25
US20170304303A1 (en) 2017-10-26
PL2861602T3 (pl) 2017-05-31
GB201209015D0 (en) 2012-07-04
EP3106464A1 (en) 2016-12-21
KR20200113027A (ko) 2020-10-05
WO2013175205A1 (en) 2013-11-28
AU2018201653A1 (en) 2018-03-29
US9376445B2 (en) 2016-06-28
ZA201408253B (en) 2015-12-23
PT2861602T (pt) 2016-11-14
ES2602308T3 (es) 2017-02-20
EA201492169A1 (ru) 2015-04-30
US9737536B2 (en) 2017-08-22
CN107344942A (zh) 2017-11-14
US20160184306A1 (en) 2016-06-30
BR112014029280A2 (pt) 2017-06-27
CN107344942B (zh) 2020-09-25
KR102161101B1 (ko) 2020-10-20
IL252033B (en) 2019-12-31
IL235805A (en) 2017-05-29
DK3106464T3 (da) 2020-03-23
EP2861602A1 (en) 2015-04-22
CN104640867A (zh) 2015-05-20
MX2014014274A (es) 2015-06-17
HRP20200580T1 (hr) 2020-10-02
SMT201600421B (it) 2017-01-10
SI2861602T1 (sl) 2017-03-31
IL271330A (en) 2020-01-30
HUE049445T2 (hu) 2020-09-28
CA2873956C (en) 2021-03-23
EP2861594B1 (en) 2016-08-24
DK2861602T3 (en) 2016-11-28
HK1209423A1 (en) 2016-04-01
LT3106464T (lt) 2020-04-10
ES2782088T3 (es) 2020-09-10
AU2013265001A1 (en) 2014-12-18
JP2015517561A (ja) 2015-06-22
CA2873956A1 (en) 2013-11-28
US20150119404A1 (en) 2015-04-30
JP2017206534A (ja) 2017-11-24
AU2017201421A1 (en) 2017-03-23
EA025579B1 (ru) 2017-01-30
JP6378404B2 (ja) 2018-08-22
CY1118274T1 (el) 2017-06-28
MX355303B (es) 2018-04-12
EP2861602B1 (en) 2016-08-10
BR112014029280B1 (pt) 2022-10-04
EP2861594A1 (en) 2015-04-22
US20180360833A1 (en) 2018-12-20
ES2602193T3 (es) 2017-02-20
CN104640867B (zh) 2017-07-21
PT3106464T (pt) 2020-04-03
WO2013175206A1 (en) 2013-11-28
LT2861602T (lt) 2016-11-10
SG11201407755UA (en) 2014-12-30
EP3106464B1 (en) 2020-01-08
SI3106464T1 (sl) 2020-12-31
IL252033A0 (en) 2017-06-29
AU2017201421B2 (en) 2017-12-07
JP2015517562A (ja) 2015-06-22
US20200289508A1 (en) 2020-09-17
IL271330B (en) 2021-02-28
SMT202000210T1 (it) 2020-05-08
IL235805A0 (en) 2015-02-01
US10485801B2 (en) 2019-11-26
HUE031664T2 (en) 2017-07-28
IN2014MN02393A (el) 2015-08-21
SG10201703527WA (en) 2017-06-29
KR20150023401A (ko) 2015-03-05
US9309254B2 (en) 2016-04-12
US20160263115A1 (en) 2016-09-15
US20150166551A1 (en) 2015-06-18
HRP20161349T1 (hr) 2017-01-27
RS60368B1 (sr) 2020-07-31
AU2013265001B2 (en) 2016-12-01

Similar Documents

Publication Publication Date Title
CY1124311T1 (el) Παρεμποδιστες dna-pk
CY1125436T1 (el) Αναστολεις dna-pk
CY1124928T1 (el) Αναστολεις πυραζολυλο κινοξαλινο κινασης
CY1121793T1 (el) Εκλεκτικοι αναστολεις pi3k δελτα
CY1124499T1 (el) Λιπιδια για συστασεις διανομης θεραπευτικου παραγοντα
CY1123476T1 (el) Τροποποιητες πυρηνικης μεταφορας και χρησεις αυτων
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124000T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1121170T1 (el) Νεες ενωσεις ως ρυθμιστες πρωτεϊνικων κινασων
CY1121076T1 (el) Τρικυκλικες ενωσεις ως αντικαρκινικοι παραγοντες
CY1123044T1 (el) Νεες ενωσεις
CY1123953T1 (el) Καθυστερημενης απελευθερωσης συνθεσεις λινακλοτιδης
CY1120730T1 (el) Απο του στοματος χορηγουμενη δοσολογια ενωσεων glp-1
CY1121225T1 (el) Συμπυκνωμενες iμιδαζολυλιμιδαζολες ως αντιiκες ενωσεις
CY1121517T1 (el) Μη φουκοζυλιωμενα αντισωματα enanti-fgfr2iiib
CY1118379T1 (el) Αναστολεις ιου ηπατιτιδας c
CY1117372T1 (el) Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες και η χρηση τους
CY1121742T1 (el) Αντισωματα s100a4 και θεραπευτικες χρησεις αυτων
CY1118680T1 (el) Φαρμακευτικη συνθεση
CY1116775T1 (el) Παραγωγα πυριμιδονης ως αναστολεις της ιστικης τρανσγλουταμινασης
CY1120204T1 (el) Αμορφη στερεα διασπορα για χρηση σε θεραπεια καρκινου του εγκεφαλο
CY1123490T1 (el) Συνθεσεις που προερχονται απο χιτοζανη
EA201590343A1 (ru) Алкилпиримидиновые производные для лечения вирусных инфекций и дальнейших заболеваний
CY1118900T1 (el) Δικυκλικως υποκατεστημενες ουρακιλες και η χρηση αυτων